Loading...
•
Dec 31, 2024
Treace Q4 2024 Earnings Report
Treace Medical Concepts reported its financial results for the fourth quarter and full year ended December 31, 2024.
Key Takeaways
Treace Medical Concepts reported a 10% increase in revenue for Q4 2024, reaching $68.7 million, and significantly improved its net loss and Adjusted EBITDA compared to the same period in 2023, driven by product mix shift, adoption of newer technologies, and increased bunion procedure kits sold.
Fourth quarter 2024 revenue increased 10% to $68.7 million compared to the same period in 2023.
Net loss for Q4 2024 improved to ($0.5) million from ($6.3) million in Q4 2023.
Adjusted EBITDA for Q4 2024 significantly increased to $11.1 million from $2.6 million in Q4 2023.
The company added 280 new active surgeons in 2024, ending the year with 3,135 active surgeons, a 10% increase from the prior year.
Forward Guidance
Treace Medical Concepts expects full-year 2025 revenue to be between $224 million and $230 million, representing a growth of 7% to 10% compared to full-year 2024, and anticipates achieving breakeven Adjusted EBITDA for the full-year 2025.
Positive Outlook
- Anticipated revenue growth of 7% to 10% for full-year 2025.
- Expectation of breakeven Adjusted EBITDA for full-year 2025.
- Continued execution on strategic plan and launch of new technologies.
- Expanded bunion portfolio to address evolving surgeon needs.
- Further penetration in the bunion market.
Challenges Ahead
- Potential impact of increased competition.
- Challenges related to accelerating adoption of MIS osteotomy solutions.
- Risks and uncertainties inherent in forward-looking statements.
- Factors that could cause actual results to differ materially from expectations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...